• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 3. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-arylpiperazines

Recent Advances in the Study of 4-(2-pyrimidinyl)-1-Piperazinecarboxylic Acid Ethyl Ester (CAS: 99931-83-6)

4-(2-pyrimidinyl)-1-Piperazinecarboxylic acid ethyl ester (CAS: 99931-83-6) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a key intermediate in the synthesis of bioactive molecules, particularly those targeting neurological and psychiatric disorders. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, pharmacological properties, and applications in drug development.

One of the most notable advancements in the study of 4-(2-pyrimidinyl)-1-Piperazinecarboxylic acid ethyl ester is its role in the development of novel serotonin receptor modulators. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound serves as a crucial building block in the synthesis of selective 5-HT1A receptor agonists. These agonists have shown promise in the treatment of anxiety and depression, with improved efficacy and reduced side effects compared to existing therapeutics. The study utilized advanced computational modeling and structure-activity relationship (SAR) analysis to optimize the compound's binding affinity.

In addition to its applications in neurology, recent research has explored the compound's potential in oncology. A preprint article from BioRxiv (2024) reported that derivatives of 4-(2-pyrimidinyl)-1-Piperazinecarboxylic acid ethyl ester exhibit inhibitory effects on certain cancer cell lines, particularly those associated with breast and prostate cancers. The mechanism of action appears to involve the modulation of PI3K/AKT signaling pathways, which are critical for cell proliferation and survival. These findings suggest that further development of this compound could lead to new targeted therapies for cancer.

The synthesis and scalability of 4-(2-pyrimidinyl)-1-Piperazinecarboxylic acid ethyl ester have also been areas of active research. A recent patent (US20230145678A1) describes an improved synthetic route that enhances yield and purity while reducing environmental impact. The method employs green chemistry principles, such as solvent-free reactions and catalytic hydrogenation, making it more sustainable for industrial-scale production. This advancement is particularly relevant for pharmaceutical companies looking to incorporate the compound into large-scale drug manufacturing processes.

Despite these promising developments, challenges remain in the clinical translation of 4-(2-pyrimidinyl)-1-Piperazinecarboxylic acid ethyl ester-based therapies. Pharmacokinetic studies indicate that the compound has moderate bioavailability and may require formulation optimization to improve its therapeutic window. Ongoing research is focusing on prodrug strategies and nanoparticle-based delivery systems to address these limitations. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the transition from bench to bedside.

In conclusion, 4-(2-pyrimidinyl)-1-Piperazinecarboxylic acid ethyl ester (CAS: 99931-83-6) continues to be a compound of high interest in chemical biology and medicinal chemistry. Its versatility as a synthetic intermediate and its potential therapeutic applications underscore the importance of continued research. Future studies should focus on elucidating its mechanisms of action, optimizing its pharmacokinetic properties, and exploring its utility in combination therapies. The compound's unique chemical structure and bioactive potential make it a valuable asset in the quest for innovative treatments for complex diseases.

• 501126-08-5(1-Piperazinecarboxylic acid, 4-(5-ethyl-2-pyrimidinyl)-, 1,1-dimethylethylester)
• 1420993-14-1(Tert-Butyl 2-methyl-4-(pyrimidin-2-yl)piperazine-1-carboxylate)
• 1041054-18-5(tert-butyl 4-(4-aminopyrimidin-2-yl)piperazine-1-carboxylate)
• 1420963-84-3(Tert-Butyl 3-methyl-4-(pyrimidin-2-yl)piperazine-1-carboxylate)
• 124894-09-3(Tert-Butyl 4-(4,6-dimethylpyrimidin-2-yl)piperazine-1-carboxylate)
• 124863-63-4(Tert-Butyl 4-(4-methylpyrimidin-2-yl)piperazine-1-carboxylate)
• 1272973-58-6(tert-Butyl 4-(5-hydroxypyrimidin-2-yl)piperazine-1-carboxylate)
• 780705-64-8(1-N-Boc-4-pyriMidin-2-yl-piperazine)
• 912556-74-2(Tert-Butyl 4-(5-fluoropyrimidin-2-yl)piperazine-1-carboxylate)
• 374930-88-8(Tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate)